首页 | 本学科首页   官方微博 | 高级检索  
     

非上呼吸消化道结外NK/T细胞淋巴瘤的不良预后因素分析
引用本文:马咪静,杨珍珍,尹美凤,杨万秋,丁梦杰,朱利楠,董萌,张蕾,李鑫,孙振昌,李玲,王冠男,张旭东,张明智,陈清江. 非上呼吸消化道结外NK/T细胞淋巴瘤的不良预后因素分析[J]. 中国肿瘤临床, 2018, 45(18): 939-942. DOI: 10.3969/j.issn.1000-8179.2018.18.742
作者姓名:马咪静  杨珍珍  尹美凤  杨万秋  丁梦杰  朱利楠  董萌  张蕾  李鑫  孙振昌  李玲  王冠男  张旭东  张明智  陈清江
作者单位:①.郑州大学第一附属医院肿瘤内科(郑州市450052)
基金项目:国家自然科学基金面上项目81470364
摘    要:  目的  分析非上呼吸消化道来源的结外NK/T细胞淋巴瘤(non-upper aerodigestive tract extranodal NK/T-cell lymphoma,NUAT-ENKTCL)的不良预后因素。  方法  回顾性分析郑州大学第一附属医院2011年1月至2015年12月收治的20例NUAT-NKTCL患者临床资料,采用Kaplan-Meier法进行生存分析,应用Log-Rank法检验对EBER表达、年龄、性别、乳酸脱氢酶(lactic dehydrogenase,LDH)水平和治疗前外周血EBV-DNA拷贝数等进行单因素分析。  结果  20例患者中,男女比为13:7。中位年龄为39(12~66)岁,其中≥60岁3例(15%), < 60岁17例(85%)。Ann Arbor分期:Ⅰ、Ⅱ期8例(40%),Ⅲ、Ⅳ期12例(60%)。LDH水平升高12例(60%)。治疗前外周血EBV-DNA拷贝数增加11例(55%)。病变组织中EBER(+)13例(65%)。患者截至随访时间死亡4例,生存16例,中位总生存期(median overall survival,mOS)为15.4个月,中位无进展生存期(median progression free survival,mPFS)为8个月。完全缓解(complete response,CR)11例(55%),部分缓解(partial response,PR)5例(25%),客观缓解率(objective response rate,ORR)为80%。单因素分析显示年龄与预后呈显著相关性。  结论  EBER的表达并不影响NUAT-ENKTCL患者的预后,年龄≥60岁患者预后较差。 

关 键 词:非上呼吸消化道NK/T细胞淋巴瘤   EBER表达   生存分析   预后
收稿时间:2018-07-15

Analysis of adverse prognostic factors of non-upper aerodigestive tract extranodal NK/T-cell lymphoma
Affiliation:①.Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China②.Lymphoma Diagnosis and Treatment Center of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China③.The Third Affiliated Hospital of Xinxiang Medical College, Xinxiang 453000, China④.Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Abstract:  Objective  To investigate the prognostic factors of non-upper aerodigestive tract extranodal NK/T- cell lymphoma (NUATNKTCL).  Methods  Samples from twenty patients with NUAT-NKTCL, who were treated in The First Affiliated Hospital of Zhengzhou University between January 2011 and December 2015, were collected. The overall survival (OS) and progression-free survival (PFS) time of these patients were estimated by the Kaplan-Meier method. Through the log-rank test, the survival curves were compared among EBER expression, age, lactate dehydrogenase (LDH) level, EBV-DNA copies, and gender.  Results  The male-female ratio of patients was 13:7. The median age was 39 years (range 12-66), with 3 patients above 60 years (15%) and the others below 60 years (85%). Forty percent of the patients were Ann-Arbor stage Ⅰ/Ⅱ and 60% of them were Ann-Arbor stage Ⅲ/Ⅳ. Twelve patients (60%) had a high level of LDH. Eleven patients had a high level of EBV-DNA copies in peripheral blood (55%) before treatment. Thirteen patients were EBER positive. Among the 20 patients, 4 patients died and 16 survived. The median OS was 15.4 months, and the median PFS was 8 months. Eleven patients received CR, 5 achieved PR while the ORR was 80%. The Log-rank test showed a significant association between age and prognosis (P=0.001).  Conclusions  There was no correlation between EBER expression and prognosis of NUAT-NKTCL. Patients over 60 years of age had a poor prognosis. 
Keywords:
点击此处可从《中国肿瘤临床》浏览原始摘要信息
点击此处可从《中国肿瘤临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号